Premium
Circulating microRNA profiling and their association with hypoadiponectinemia
Author(s) -
Hassan Furqan,
Sammy Sanjay A,
Trecartin Andrew,
Alley Joshua B,
Bovenzi Frank,
Bohman Danna,
Fitzgerald Laura,
Prot JeanMatthieu,
Schuler Michael L,
ArizaNieto Magnolia
Publication year - 2013
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.27.1_supplement.1192.18
Subject(s) - adiponectin , microrna , medicine , obesity , metabolic syndrome , diabetes mellitus , type 2 diabetes mellitus , oncology , bioinformatics , cancer research , biology , endocrinology , insulin resistance , genetics , gene
Hypoadiponectinemia is frequently observed in individuals with cardiovascular disease, type 2 diabetes mellitus, obesity, and obesity related cancers among many other metabolic disorders. MicroRNAs appear to play a regulatory role in the expression of adiponectin, but this role remains unclear at this time. Consequently, the aim is to identify microRNAs involved in the regulation and expression of adiponectin. Replication of clinical in vivo observations will be attempted in vitro using the genotyped “body‐on‐a‐chip” BOAC systems. The goal is to have an in vitro model to identify nutritionally induced microRNA profiles. MicroRNA profile assays are performed in pools of 4 groups of donors. Group 1‐BMI >; 40 prior to bariatric surgery, 2‐BMI<30 after bariatric surgery; 3‐patients diagnosed with metabolic syndrome 4‐controls without metabolic syndrome. Circulating microRNAs are isolated from the plasma of patients corresponding to IRB approved clinical trial GHS # 1207–27. The assays are performed with the qiagen human plasma miRNA PCR array (MIHS‐106Z) with internal normalization control C. elegans miR‐39 spike. Circulating microRNA profiles are correlated with circulating levels of total adiponectin and other clinical markers of metabolism. Funding Cornell University Center on the Microenvironment and Metastasis (CMM) outreach pilot grant and Guthrie Foundation Investigator‐Initiated Research Grant.